Allergan: The Second Engine It BoughtNarrow moat

AbbVie (ABBV) — moat facet

The $64 billion Allergan deal gave AbbVie a growing medical Botox and neuroscience business and a shrinking cosmetics business.

AbbVie's second moat facet was bought. It completed the acquisition of Allergan on 8 May 2020 for total consideration of $64,084 million1, the largest in its history, to diversify away from Humira. Six years later the verdict is mixed but mostly positive.

Allergan-heavy businesses ($M)7,717Neuroscience 202310,767Neuroscience 20255,294Aesthetics 20234,860Aesthetics 2025AbbVie Forms 10-K; group totals calculated
One half growing, the other shrinking.

The success is neuroscience. Botox Therapeutic, Vraylar and Allergan's migraine drugs anchor a business that sold $10,767 million in 20252 and grew 20.3% in the second quarter of 20263. Botox Therapeutic passed $1 billion in a quarter for the first time in early 20264.

The disappointment is the consumer side. Aesthetics revenue fell from $5,333 million in 2022 to $4,860 million in 202556, and American Botox Cosmetic sales fell 11% in 20257. Eye care shrank each year and is no longer reported separately8.

The price shows on the balance sheet. Goodwill was $35,640 million and intangible assets $52,641 million at the end of 20259, together about 66% of total assets10. Amortisation of intangibles was $7,377 million in 202511.

The deal was large even by AbbVie's standards. It paid $39,675 million in cash and $23,979 million in stock12, issuing shares to Allergan's owners, and took on Allergan's debt. Six years later AbbVie's net debt is still about $64 billion13. The purchase bought growth in neuroscience; the balance sheet is still paying for it.

Allergan gave AbbVie a narrow second moat in medical Botox and neuroscience and a weak one in aesthetics. The test is neuroscience growth through the government-set prices for Vraylar in 2027 and Botox in 202814; growth above 10% through those years would say the purchase built something durable.

Moat trajectory: Holding steady

Neuroscience growing 20%; aesthetics and eye care shrinking.

The number that tests this moat
Reported
Neuroscience and aesthetics revenue, latest quarter
$4,510M combined (Q2 2026): neuroscience +20.3%, aesthetics +0.3%

The Allergan businesses together; neuroscience outgrowing aesthetics decline is what makes the deal work.

Source: AbbVie Q2 2026 results release ↗
Aspects of the moat
DIG DEEPER 01
Botox Therapeutic Passed $1 Billion a Quarter
Medical Botox now sells more than $1 billion a quarter and faces no biosimilar, only a Medicare price from 2028.
DIG DEEPER 02
Aesthetics: A Business Shrinking Since 2022
AbbVie's cosmetics business has shrunk every year since 2022, and its flagship Botox Cosmetic lost share in America in 2025.
DIG DEEPER 03
Neuroscience: The Second Growth Engine
AbbVie's neuroscience drugs, mostly bought with Allergan, sell $10.8 billion a year and are growing 20%.
DIG DEEPER 04
Eye Care: The Allergan Business That Shrinks
Allergan's eye-care drugs have shrunk every year under AbbVie, and in 2026 AbbVie stopped reporting them separately.
⚠ Threats to the moat
⚠ THREAT 01
Intangibles Are Two-Thirds of the Assets
About two-thirds of AbbVie's assets are goodwill and intangibles, the accumulated price of the companies it bought.
⚠ THREAT 02
Aesthetics Depends on Consumer Confidence
Botox Cosmetic and Juvederm are paid for by consumers, so AbbVie's aesthetics business rises and falls with their confidence.
References
  1. ReportedIt completed the acquisition of Allergan on 8 May 2020 for total consideration of $64,084 million, the largest in its history, to diversify away from Humira.
    AbbVie Form 10-K for fiscal 2020 - the Allergan acquisition and its total consideration. — FY2020 · publ. February 2021 · source ↗
  2. ReportedBotox Therapeutic, Vraylar and Allergan's migraine drugs anchor a business that sold $10,767 million in 2025 and grew 20.3% in the second quarter of 2026.
    AbbVie Form 10-K for fiscal 2025 - Item 7 MD&A: net revenues by product and region, and rebates. — FY2025 · publ. 20 February 2026 · source ↗
  3. ReportedBotox Therapeutic, Vraylar and Allergan's migraine drugs anchor a business that sold $10,767 million in 2025 and grew 20.3% in the second quarter of 2026.
    AbbVie second-quarter 2026 results release, Form 8-K exhibit 99.1. — Q2 2026 · publ. 31 July 2026 · source ↗
  4. ReportedBotox Therapeutic passed $1 billion in a quarter for the first time in early 2026.
    Quartz, AbbVie first-quarter 2026 results: global Botox Therapeutic sales passed $1 billion in a quarter for the first time. — Q1 2026 · publ. 29 April 2026 · source ↗
  5. ReportedAesthetics revenue fell from $5,333 million in 2022 to $4,860 million in 2025, and American Botox Cosmetic sales fell 11% in 2025.
    AbbVie Form 10-K for fiscal 2024 - product revenue for 2022-2024, product concentration, the CEO succession and the emraclidine impairment. — FY2024 · publ. February 2025 · source ↗
  6. ReportedAesthetics revenue fell from $5,333 million in 2022 to $4,860 million in 2025, and American Botox Cosmetic sales fell 11% in 2025.
    AbbVie Form 10-K for fiscal 2025 - Item 7 MD&A: net revenues by product and region, and rebates. — FY2025 · publ. 20 February 2026 · source ↗
  7. ReportedAesthetics revenue fell from $5,333 million in 2022 to $4,860 million in 2025, and American Botox Cosmetic sales fell 11% in 2025.
    AbbVie Form 10-K for fiscal 2025 - Item 7 MD&A: net revenues by product and region, and rebates. — FY2025 · publ. 20 February 2026 · source ↗
  8. ReportedEye care shrank each year and is no longer reported separately.
    AbbVie Form 10-Q for the quarter ended 30 June 2026 - product revenue, the balance sheet, cash flow and the Apogee agreement. — Q2 2026 · publ. 3 August 2026 · source ↗
  9. ReportedGoodwill was $35,640 million and intangible assets $52,641 million at the end of 2025, together about 66% of total assets.
    AbbVie Form 10-K for fiscal 2025 - financial statements and notes: earnings, cash flow, balance sheet, acquisitions and contingent consideration. — FY2025 · publ. 20 February 2026 · source ↗
  10. Moat Explorer calcGoodwill was $35,640 million and intangible assets $52,641 million at the end of 2025, together about 66% of total assets.
    Moat Explorer calculation from AbbVie's reported product revenue and financial statements ($ millions unless stated). Therapeutic areas 2025: immunology 17,562 + 8,304 + 4,540 = 30,406; neuroscience 3,621 + 3,769 + 1,271 + 1,036 + 482 + 381 + 207 = 10,767; oncology 2,869 + 2,792 + 690 + 271 + 33 = 6,655; aesthetics 2,602 + 993 + 1,265 = 4,860; eye care 493 + 410 + 197 + 1,009 = 2,109; other key products 1,317 + 1,512 + 907 = 3,736; all other 2,627; eye care and other products 2,109 + 3,736 + 2,627 = 8,472; total 61,160. 2024: immunology 11,718 + 5,971 + 8,993 = 26,682; neuroscience 8,999; oncology 6,555; aesthetics 5,176; eye care and other 2,242 + 3,648 + 3,032 = 8,922. 2023: 7,763 + 3,969 + 14,404 = 26,136; neuroscience 7,717; oncology 5,915; aesthetics 5,294; eye care and other 2,415 + 3,806 + 3,035 = 9,256. 2022: 5,165 + 2,522 + 21,237 = 28,924; neuroscience 6,528; oncology 6,577; aesthetics 5,333; eye care and other 2,701 + 3,854 + 4,137 = 10,692. Growth 2025: immunology 30,406 / 26,682 - 1 = 14.0%; neuroscience 10,767 / 8,999 - 1 = 19.6%. Immunology and neuroscience 30,406 + 10,767 = 41,173, 41,173 / 61,160 = 67.3%. Immunology share 30,406 / 61,160 = 49.7%. Skyrizi + Rinvoq: 5,165 + 2,522 = 7,687 (2022); 7,763 + 3,969 = 11,732 (2023); 11,718 + 5,971 = 17,689 (2024); 17,562 + 8,304 = 25,866 (2025); H1 2026 9,988 + 4,644 = 14,632; Q2 2026 5,505 + 2,525 = 8,030, 8,030 / 16,990 = 47.3%; 2026 plan 21.5 + 10.1 = 31.6 bn. Shares of revenue 7,687 / 58,054 = 13.2%; 11,732 / 54,318 = 21.6%; 17,689 / 56,334 = 31.4%; 25,866 / 61,160 = 42.3%. Humira: 4,540 / 21,237 - 1 = -78.6%; share 8,993 / 56,334 = 16.0% (2024), 4,540 / 61,160 = 7.4% (2025). Rebates: 65.1 / 61.16 = 1.06; 65.1 / 18.8 = 3.5 times (2019-2025) against net revenues 61,160 / 33,266 = 1.8 times; gross sales 61.2 + 65.1 = 126.3 bn, 126.3 / 61.2 = 2.1 times; managed care 22,307 / 61,160 = 36.5%; Medicaid and Medicare 21,283 / 61,160 = 34.8%; payers 22,307 + 21,283 = 43,590, 43,590 / 61,160 = 71.3%. Geography: US 46,603 / 61,160 = 76.2%; international 14,557 / 61,160 = 23.8%. Gross margin 2025 (61,160 - 18,204) / 61,160 = 70.2%. Government-set price products, 2025 sales: 2,869 + 3,621 + 907 + 3,769 = 11,166, 11,166 / 61,160 = 18.3%. Goodwill and intangibles 35,640 + 52,641 = 88,281, 88,281 / 133,960 = 65.9%. Eye care share 2,109 / 61,160 = 3.4%; aesthetics share 4,860 / 61,160 = 7.9%. Net debt 30 June 2026: 62,481 + 8,341 - 6,569 = 64,253; net debt / operating cash flow 64,253 / 19,030 = 3.4 years. Free cash flow 2025: 19,030 - 1,214 = 17,816; dividends paid 11,657 / 17,816 = 65.4%; operating cash flow / dividends 19,030 / 11,657 = 1.6; dividends declared / net earnings 11,819 / 4,226 = 2.8; dividends per share 6.65 / 1.75 = 3.8 times (2014-2025). Free cash flow yield 17,816 / 468,500 = 3.8%; free cash flow per share 17,816 / 1,771 = 10.06. 2026 adjusted EPS guidance midpoints: (14.37 + 14.57) / 2 = 14.47; (13.96 + 14.16) / 2 = 14.06; (14.08 + 14.28) / 2 = 14.18; (13.91 + 14.11) / 2 = 14.01; (13.87 + 14.07) / 2 = 13.97. Ubrelvy and Qulipta Q2 2026 392 + 350 = 742; 2025 1,271 + 1,036 = 2,307. Skyrizi share 17,562 / 61,160 = 28.7%. Juvederm 993 / 1,428 - 1 = -30.5%. Aesthetics 4,860 / 5,176 - 1 = -6.1%. Gross margin 2023 (54,318 - 20,415) / 54,318 = 62.4%. Skyrizi + Rinvoq 2021 2,939 + 1,651 = 4,590; 2022 7,687 / 21,237 = 36% - balance sheet, cash flow, dividends and valuation. — 2015-2026 · publ. September 2026 · source ↗
    Method: Arithmetic on figures reported in AbbVie's Forms 10-K, 10-Q, results releases, the Q4 2025 call and market data; operands shown in the source line.
  11. ReportedAmortisation of intangibles was $7,377 million in 2025.
    AbbVie Form 10-K for fiscal 2025 - financial statements and notes: earnings, cash flow, balance sheet, acquisitions and contingent consideration. — FY2025 · publ. 20 February 2026 · source ↗
  12. ReportedIt paid $39,675 million in cash and $23,979 million in stock, issuing shares to Allergan's owners, and took on Allergan's debt.
    AbbVie Form 10-K for fiscal 2020 - the Allergan acquisition and its total consideration. — FY2020 · publ. February 2021 · source ↗
  13. Moat Explorer calcSix years later AbbVie's net debt is still about $64 billion.
    Moat Explorer calculation from AbbVie's reported product revenue and financial statements ($ millions unless stated). Therapeutic areas 2025: immunology 17,562 + 8,304 + 4,540 = 30,406; neuroscience 3,621 + 3,769 + 1,271 + 1,036 + 482 + 381 + 207 = 10,767; oncology 2,869 + 2,792 + 690 + 271 + 33 = 6,655; aesthetics 2,602 + 993 + 1,265 = 4,860; eye care 493 + 410 + 197 + 1,009 = 2,109; other key products 1,317 + 1,512 + 907 = 3,736; all other 2,627; eye care and other products 2,109 + 3,736 + 2,627 = 8,472; total 61,160. 2024: immunology 11,718 + 5,971 + 8,993 = 26,682; neuroscience 8,999; oncology 6,555; aesthetics 5,176; eye care and other 2,242 + 3,648 + 3,032 = 8,922. 2023: 7,763 + 3,969 + 14,404 = 26,136; neuroscience 7,717; oncology 5,915; aesthetics 5,294; eye care and other 2,415 + 3,806 + 3,035 = 9,256. 2022: 5,165 + 2,522 + 21,237 = 28,924; neuroscience 6,528; oncology 6,577; aesthetics 5,333; eye care and other 2,701 + 3,854 + 4,137 = 10,692. Growth 2025: immunology 30,406 / 26,682 - 1 = 14.0%; neuroscience 10,767 / 8,999 - 1 = 19.6%. Immunology and neuroscience 30,406 + 10,767 = 41,173, 41,173 / 61,160 = 67.3%. Immunology share 30,406 / 61,160 = 49.7%. Skyrizi + Rinvoq: 5,165 + 2,522 = 7,687 (2022); 7,763 + 3,969 = 11,732 (2023); 11,718 + 5,971 = 17,689 (2024); 17,562 + 8,304 = 25,866 (2025); H1 2026 9,988 + 4,644 = 14,632; Q2 2026 5,505 + 2,525 = 8,030, 8,030 / 16,990 = 47.3%; 2026 plan 21.5 + 10.1 = 31.6 bn. Shares of revenue 7,687 / 58,054 = 13.2%; 11,732 / 54,318 = 21.6%; 17,689 / 56,334 = 31.4%; 25,866 / 61,160 = 42.3%. Humira: 4,540 / 21,237 - 1 = -78.6%; share 8,993 / 56,334 = 16.0% (2024), 4,540 / 61,160 = 7.4% (2025). Rebates: 65.1 / 61.16 = 1.06; 65.1 / 18.8 = 3.5 times (2019-2025) against net revenues 61,160 / 33,266 = 1.8 times; gross sales 61.2 + 65.1 = 126.3 bn, 126.3 / 61.2 = 2.1 times; managed care 22,307 / 61,160 = 36.5%; Medicaid and Medicare 21,283 / 61,160 = 34.8%; payers 22,307 + 21,283 = 43,590, 43,590 / 61,160 = 71.3%. Geography: US 46,603 / 61,160 = 76.2%; international 14,557 / 61,160 = 23.8%. Gross margin 2025 (61,160 - 18,204) / 61,160 = 70.2%. Government-set price products, 2025 sales: 2,869 + 3,621 + 907 + 3,769 = 11,166, 11,166 / 61,160 = 18.3%. Goodwill and intangibles 35,640 + 52,641 = 88,281, 88,281 / 133,960 = 65.9%. Eye care share 2,109 / 61,160 = 3.4%; aesthetics share 4,860 / 61,160 = 7.9%. Net debt 30 June 2026: 62,481 + 8,341 - 6,569 = 64,253; net debt / operating cash flow 64,253 / 19,030 = 3.4 years. Free cash flow 2025: 19,030 - 1,214 = 17,816; dividends paid 11,657 / 17,816 = 65.4%; operating cash flow / dividends 19,030 / 11,657 = 1.6; dividends declared / net earnings 11,819 / 4,226 = 2.8; dividends per share 6.65 / 1.75 = 3.8 times (2014-2025). Free cash flow yield 17,816 / 468,500 = 3.8%; free cash flow per share 17,816 / 1,771 = 10.06. 2026 adjusted EPS guidance midpoints: (14.37 + 14.57) / 2 = 14.47; (13.96 + 14.16) / 2 = 14.06; (14.08 + 14.28) / 2 = 14.18; (13.91 + 14.11) / 2 = 14.01; (13.87 + 14.07) / 2 = 13.97. Ubrelvy and Qulipta Q2 2026 392 + 350 = 742; 2025 1,271 + 1,036 = 2,307. Skyrizi share 17,562 / 61,160 = 28.7%. Juvederm 993 / 1,428 - 1 = -30.5%. Aesthetics 4,860 / 5,176 - 1 = -6.1%. Gross margin 2023 (54,318 - 20,415) / 54,318 = 62.4%. Skyrizi + Rinvoq 2021 2,939 + 1,651 = 4,590; 2022 7,687 / 21,237 = 36% - balance sheet, cash flow, dividends and valuation. — 2015-2026 · publ. September 2026 · source ↗
    Method: Arithmetic on figures reported in AbbVie's Forms 10-K, 10-Q, results releases, the Q4 2025 call and market data; operands shown in the source line.
  14. ReportedThe test is neuroscience growth through the government-set prices for Vraylar in 2027 and Botox in 2028; growth above 10% through those years would say the purchase built something durable.
    AbbVie Form 10-K for fiscal 2025 - Item 1A risk factors, patents and exclusivity, government pricing and legal proceedings. — FY2025 · publ. 20 February 2026 · source ↗
Sources
Generated September 25, 2026